Company intelligence / Profile preview

NextVivo

Palo Alto, California, United Statesnextvivo.bio ↗

Ownership: Private
Employees: ~6
Development stage: Preclinical

Overview

NextVivo has developed an immune organoid technology that creates 3D human tissue models retaining all key cell types, including immune cells. This allows for the generation and testing of therapies in immune-relevant human-derived systems before clinical trials. The company aims to accelerate safer, more effective therapy development by enabling functional testing without patient risk. No clinical results reported as the focus is on preclinical modeling.

Therapeutic areas: Other
Modalities: Immune organoid technology (enables testing of various therapeutic modalities; specific drug classes not detailed)
Industry: Non-Drug Biotech

Partnerships

Khosla Ventures-led syndicate investors; no major pharma partnerships publicly listed

Beyond the preview

Go deeper on NextVivo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NextVivo.

Explore the full profile